LENVIMA(R) (lenvatinib) Plus KEYTRUDA(R) (pembrolizumab) in Combination With Transarterial Chemoembolization (TACE) Significantly Improved Progression-Free Survival Compared to TACE Alone in Patients With Unresectable, Non-Metastatic Hepatocellular Carcin
TOKYO and RAHWAY, N.J., Sep 17, 2024 - (JCN Newswire) - Eisai and Merck & Co., Inc., Rahway, NJ, USA
